Oragenics, Inc. develops antibiotics for infectious diseases in the United States. Its lead product candidate under development is OG716, an antibiotic for the treatment of Clostridium difficile. The company also engages in the development and commercialization of Terra CoV-2, a vaccine product candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. Its product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. The company has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement with Precigen, Inc. and ILH Holdings, Inc. for the development and production of lantibiotics, a peptide antibiotic that are naturally produced in gram-positive bacteria. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.
IPO Year:
Exchange: AMEX
Website: oragenics.com
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
4 - ORAGENICS INC (0001174940) (Issuer)
8-K - ORAGENICS INC (0001174940) (Filer)
8-K - ORAGENICS INC (0001174940) (Filer)
EFFECT - ORAGENICS INC (0001174940) (Filer)
S-1/A - ORAGENICS INC (0001174940) (Filer)
S-1/A - ORAGENICS INC (0001174940) (Filer)
S-1 - ORAGENICS INC (0001174940) (Filer)
8-K - ORAGENICS INC (0001174940) (Filer)
S-8 - ORAGENICS INC (0001174940) (Filer)
8-K - ORAGENICS INC (0001174940) (Filer)
10-Q - ORAGENICS INC (0001174940) (Filer)
Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00
TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic
SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith
SARASOTA, Fla., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today announced the conversion of its remaining outstanding convertible Series A and Series B Preferred Shares into common stock. The conversion helps simplify the company's capital structure and eliminates approximately $2.35 million in liquidation preference, effectively removing a significant overhang on the company's stock. Holders of the Company's remaining 5,417,000 Series A Preferred Shares and 4,050,000 Series B Preferred Shares exercised their right to convert their shares into a total of approximately 22,000 c
SARASOTA, Fla., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE:OGEN), a company focused on developing new treatments for brain-related health conditions, announced it will be presenting at the Centurion One Capital 2nd Annual Bahamas Summit to be held at the Rosewood Baha Mar Hotel on October 22-23, 2024, in Nassau, Bahamas. Michael Redmond, President of Oragenics, will participate in a corporate presentation and Q&A session on October 22, 2024 at 1:20 pm ET. Details for the presentation are as follows:Date: Tuesday, October 22, 2024Time: 1:20 p.m. EDTPresenter: Michael Redmond, President of OragenicsRegister for the event by clicking here. About Oragenics: Oragenics is a develo
SARASOTA, Fla., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biopharmaceutical company committed to developing novel therapies for neurological disorders, today provided a corporate update reflecting on the company's progress throughout 2024, including key milestones in the development of ONP-002, its lead candidate for the treatment of concussions. Company Overview: A Vision for Innovation in NeurologyOragenics is focused on revolutionizing drug delivery for neurological disorders using innovative intranasal technology. The company's lead program, ONP-002, is a first-in-class neurosteroid being developed to treat moderate to severe concussions. Intranasal delivery
SARASOTA, Fla., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Oragenics Inc. (NYSE:OGEN), a company focused on developing new treatments for brain-related health conditions, has completed a key study for their new concussion drug, ONP-002. This drug is designed to be delivered through the nose, which could help it reach the brain quickly after a head injury. The recent study shows that the drug successfully targets areas inside the nose that are connected to the brain. This makes it more likely to reach and treat the brain after a concussion. Intranasal casting studies are valued by the FDA for pharmaceuticals delivered via the nasal passage and accept such studies in FDA submissions. Oragenics i
SARASOTA, Fla., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the closing of its previously announced offering of 3,078,378 shares of its common stock and pre-funded warrants to purchase up to 5,028,206 shares of common stock at an offering price of $0.55 per share and $0.549 per pre-funded warrant. Immediately after the closing of the offering, the Company has 8,659,071 shares of common stock outstanding and pre-funded warrants to acquire up to 5,028,206 shares of common stock outstanding. The exercise price of each pre-funded warrant is $0.001.
SARASOTA, Fla., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 8,106,584 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $0.55 per share (or $0.549 per pre-funded warrant in lieu thereof). The closing of the public offering is expected to occur on or about September 5, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering are anticipated to be approximately $4.45 million b
• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients • No pharmaceutical treatment is available for concussion; drug, ONP-002, could be first of its kind to treat concussion SARASOTA, Fla., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced the completion of its spray-dried formulation and filling in the nasal device for its lead candidate, ONP-002, for concussion. ONP-002 is a new chemical entity (NCE) designed to target the brain through
SARASOTA, Fla., Aug. 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("the Company"), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced recent and key 2024 business progress. The Company continues to execute its business strategy to develop and advance its lead candidate, ONP-002, for the treatment of concussion. Phase 2 human trials are being planned with anticipation of starting in the fourth quarter of this year. Achievements: Stability of ONP-002 Across a Wide Temperature Range: Demonstrated that ONP-002 is stable at high and low temperatures, eliminating the need for cumbersome cold storage. This
• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced its lead candidate for treating concussion, ONP-002, is stable across a wide temperature range, eliminating the need for cumbersome cold storage for the drug device combination. ONP-002 is a new chemical entity (NCE) designed to target the brain through a breath propelled delivery system into the nasal cavity to treat concussions. Oragenics recently co
SC 13G/A - ORAGENICS INC (0001174940) (Subject)
SC 13G/A - ORAGENICS INC (0001174940) (Subject)
SC 13G - ORAGENICS INC (0001174940) (Subject)
SC 13G - ORAGENICS INC (0001174940) (Subject)
SC 13D - ORAGENICS INC (0001174940) (Subject)
SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith
SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver
Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. James "Jim" Kelly, Neurologist, as its Chief Medical Officer, to oversee its upcoming Phase II clinical trial. Oragenics' lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion. ONP-002 is a new chemical entity (NCE) designed to target the brain through delivery into the nasal cavity and onward to the brain. A 40-patient Phase I study was completed and showed the drug to be safe and well-tolerated. In the recent past, Dr.
Oragenics, Inc. (NYSE:OGEN) (the "Company"), a company focused on developing unique, intranasal nanoparticle pharmaceuticals for the treatment of neurological disorders, today announced that, on February 12, 2024, the Company and Kimberly Murphy, the Company's Chief Executive Officer, entered into a mutually agreeable Separation Agreement (the "Separation Agreement"), pursuant to which Ms. Murphy's employment with the Company terminated effective February 12, 2024. Ms. Murphy will, however, continue to serve the Company as a member of the Company's board of directors (the "Board"). The Separation Agreement provides Ms. Murphy with the benefits under her employment agreement with the Company
Adds Clinical-Stage Product Pipeline, Expands Intranasal Drug Delivery Technologies, Names Michael Redmond as President of Oragenics Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") announces it has completed its previously announced acquisition of assets related to Odyssey Health, Inc.'s (OTCQB:ODYY) ("Odyssey") proprietary neurological drug therapies and technologies. The acquired assets include ONP-002 and a unique nasal delivery device, Odyssey's lead concussion asset, believed to be a first-in-class intranasal drug under development for the treatment of moderate-to-severe concussion in the acute through subacute phases. In preclinical animal studies, the asset demonstra
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") announced the appointments of Bruce Cassidy and John Gandolfo to the Board of Directors effective October 4, 2023. "We are delighted to welcome Bruce Cassidy and John Gandolfo to the Oragenics Board," said Charlie Pope, Chairman of Oragenics. "Bruce's deep experience in high-technology global businesses will be invaluable to Oragenics as we grow our portfolio. John's proven leadership in the life sciences, capital raising and financial management will be critical to our future. We are confident that Bruce and John will provide valuable perspectives as we continue to execute our strategy, pursue our mission to serve patients and en
Gains Nasal Delivery Technologies and Expands Product Pipeline Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company") and Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey") announce the signing of a definitive agreement under which Oragenics will acquire Odyssey's assets related to its proprietary neurological drug therapies and technologies. The assets include drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as Odyssey's proprietary powder formulation and its nasal delivery device. Odyssey will retain its other assets and operations. The asset purchase includes cash payments to Odyssey
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotechnology company dedicated to fighting infectious diseases including COVID-19, announces the appointment of Janet Huffman as Chief Financial Officer, effective March 7, 2023. Ms. Huffman is a seasoned financial executive with more than a dozen years of leadership experience at publicly traded and private healthcare companies. "Janet's extensive professional background as a public company CFO will be important to Oragenics as we drive forward with our development plans. She brings particularly valuable expertise in raising capital and M&A transactions to deliver strong strategic results. We expect that her experience in thes
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced that on December 16, 2022 the Board of Directors appointed Charles Pope as its Chairman of the Board of Directors succeeding Dr. Frederick W. Telling, who has served as a director since June 2010 and as Chairman since February 2011. Dr. Telling will remain on the Board as an independent director and as a member of both the audit and nominating and corporate governance committees. Dr. Telling stated: "It has been an honor and privilege to serve as Chairman of Oragenics for over a decade and I look forward to assisting with the Company's
Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat